Drug intelligence / Profile preview

INCB059872 + nivolumab

Development stage: Unknown
Lead developer: Incyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

**INCB059872 + nivolumab** is an investigational combination therapy tested in clinical trials for advanced small cell lung cancer (SCLC) and other advanced malignancies. INCB059872 is a small molecule inhibitor of lysine-specific histone demethylase 1A (LSD1), which may block epigenetic modification and promote anti-tumor immune responses, while nivolumab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), enhancing T-cell-mediated anti-tumor immunity. The combination is designed to leverage both epigenetic modulation and immune checkpoint blockade for synergistic anti-cancer effects[1][3].

Other names: INCB059872 + nivolumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)KDM1A (LSD1)

Beyond the preview

Go deeper on INCB059872 + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCB059872 + nivolumab.

Explore the full profile